Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 80mg atorvastatin Clear all
Not listed Phase 4 Interventional

Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions

NCT00640744
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 5, 2026, 6:41 AM EDT
Recruiting Phase 2 Interventional

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

NCT04735263
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Atorvastatin 80mg
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.

NCT01499758
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

NCT02603328
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Not applicable Interventional Results available

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648
View directory record Official record
Conditions
Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions
atorvastatin, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systems Biological Assessment of Statin Effect on Vaccine Responses

NCT06024096
View directory record Official record
Conditions
Vaccine Response
Interventions
Atorvastatin, Quadrivalent seasonal influenza vaccine
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 6:41 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

NCT03351998
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

NCT00361283
View directory record Official record
Conditions
Inflammation
Interventions
Atorvastatin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Sep 5, 2026, 6:41 AM EDT
Terminated Not applicable Interventional Results available

Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

NCT00979940
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 5, 2026, 6:41 AM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 5, 2026, 6:41 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

NCT03560882
View directory record Official record
Conditions
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
Interventions
Atorvastatin
Drug
Lead sponsor
Joaquina Baranda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin

NCT01785615
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 5, 2026, 6:41 AM EDT
Recruiting Early Phase 1 Interventional

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

NCT06961630
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery
Interventions
Rivaroxaban, Atorvastatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 5, 2026, 6:41 AM EDT
Terminated Phase 4 Interventional Results available

Statins and Endothelial Function in Patients With Coarctation of the Aorta

NCT00767572
View directory record Official record
Conditions
Coarctation of the Aorta
Interventions
atorvastatin, Sugar pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

NCT01499771
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 66 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 5, 2026, 6:41 AM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 5, 2026, 6:41 AM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
View directory record Official record
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

NCT02347098
View directory record Official record
Conditions
Acute Coronary Artery Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Results available

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

NCT01600170
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin (generic Lipitor), placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 5, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

NCT00166036
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 5, 2026, 6:41 AM EDT